LEADERSHIP

We have assembled a team with extensive experience in drug discovery, clinical development and commercial who lead our company with passion and a drive to serve our patient communities.

Anthony Quinn, M.B Ch.B, Ph.D.

President & Chief Executive Officer

Dr. Anthony Quinn most recently served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma until the company’s acquisition by Alexion Pharmaceuticals in 2015. During his tenure at Synageva, he played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency and in building the company’s research and development organization and rare disease drug pipeline. Prior to his role at Synageva, Anthony served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. Previously, he was a professor of dermatology at Barts and The London School of Medicine. He received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and a Ph.D. from the University of Newcastle upon Tyne. He completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London. Anthony currently serves as a member of the board of directors for Kaleido Biosciences, Inc. and Generation Bio.
Bio

Charles N. York II, M.B.A.

Chief Financial Officer

Charles York has raised more than $400 million in public and private financings for Aeglea, including the Company’s initial public offering in 2016. His current responsibilities include Aeglea’s corporate development, finance, accounting, facilities, human resources, and investor and public relations functions. Prior to joining Aeglea, Charles held finance leadership positions in public companies and high-growth start-ups in the life sciences and technology industries. His corporate finance transactional background includes an IPO, a private equity buyout, a corporate spin-off, and an acquisition. Charles is a Certified Public Accountant (CPA) who earned his B.S. in accounting from the University of Connecticut and his M.B.A. from the McCombs School of Business at the University of Texas at Austin, where he is now a member of the Healthcare Innovation Board.
Bio

Leslie Sloan, Ph.D.

Chief Operating Officer

Prior to joining Aeglea, Dr. Leslie Sloan served as vice president of global R&D project management and analytics, as well as president and R&D site head at Ipsen Bioscience. Previously, she held several global roles at Pfizer and Eli Lilly. Leslie has been instrumental to 15 successful new or supplemental market authorization submissions in Europe and the U.S. She was a member of the Ipsen R&D leadership team, the Pfizer R&D clinical candidate survival council and candidate quality guidelines committee and co-chair of the Bioorganic Chemistry Gordon Research Conference. Leslie earned a B.S. in chemistry and medical biology from Southeastern Oklahoma State University and a Ph.D. in bioorganic chemistry from Yale University under the direction of Dr. Alanna Schepartz.
Bio

Eric Bradford, M.D., M.B.A.

Chief Development Officer

Dr. Eric Bradford has 20 years of drug development related experience including leadership roles in clinical development, medical affairs, product strategy and commercialization. Prior to joining Aeglea, he held a number of leadership roles at GlaxoSmithKline, most recently as the clinical development leader for mepolizumab where he was responsible for overall delivery of the clinical development program spanning numerous disease states ranging from rare disease to significant respiratory conditions. Prior to this, he held positions of increasing responsibility across the R&D organization providing strategic and commercial leadership across multiple therapy areas including immuno-inflammation, infectious disease, and neurosciences. Before GlaxoSmithKline, he was a director of business development and strategic planning at DuPont Pharmaceuticals. Eric is board certified in Internal Medicine and completed his residency training at Stanford University. He received a BA in Economics from Davidson College, an M.D. from the University of North Carolina, a M.Sc. in Health Research and Policy from Stanford University, and an M.B.A. from the University of Virginia.
Bio

Michael C. Hanley, M.B.A.

Chief Commercial Officer

Mike Hanley has nearly 25 years of experience in the biopharmaceutical and healthcare industries. Prior to joining Aeglea, he served as vice president and U.S. chief commercial officer of Esteve Pharmaceuticals, S.A., where he played a key role in identifying a new corporate strategic vision and leading the establishment of a new U.S affiliate. Previously, Mike served in various roles of increasing responsibility at Horizon Therapeutics PLC, a global biopharmaceutical company, where he had P&L responsibility for the company’s rare disease portfolio. Prior to Horizon, he served in various commercial leadership roles at the U.S. affiliate of H. Lundbeck A/S, a global pharmaceutical company, where he led the launch and life cycle strategy of a product for a rare and devastating form of epilepsy. Mike holds a B.B.A. in Marketing from the University of Notre Dame and an M.B.A. from the Kellogg School of Management at Northwestern University.
Bio

Scott W. Rowlinson, Ph.D.

Vice President of Research

Dr. Scott Rowlinson joined Aeglea from Eli Lilly and Company. He has a proven track record of scientific publishing and productivity in biologics drug discovery and development using antibody, ligand and enzyme scaffolds. He has demonstrated leadership in coordinating drug discovery to clinical development in multiple therapeutic areas ranging from chronic kidney disease, oncology and inborn errors of metabolism. These efforts led to multiple successful IND submissions, the most advanced being in Phase 3 clinical development. Scott has a wealth of experience in the broader concepts of biomolecule drug development, including uncovering factors involved in clinical portfolio attrition and optimal integration of manufacturing, toxicology, bioanalytical and companion diagnostic development into molecule development. He holds a Ph.D. in physiology and biochemistry from University of Queensland in Brisbane, Australia.
Bio

Eugene Sackett

Vice President of Human Resources

Gene Sackett has over 30 years of experience focused in companies in technology, pharmaceuticals and biotechnology. Prior to joining Aeglea, Eugene served as vice president human resources at NewLink Genetics, where he played a key role in leading the company through two reorganizations due to unexpected business circumstances. Prior to NewLink, he was executive director of Human Resources at Iroko Pharmaceuticals, where he helped build the company’s first commercial organization, which supported three product launches in 18 months. Additional pharmaceutical industry experience includes roles at Cephalon and Wyeth. He began his career at Unisys Corporation, spending more than 16 years in a variety of positions with increasing leadership responsibilities supporting large, complex organizations with geographically dispersed employees and staff. Gene earned a B.S. in finance from Ithaca College.
Bio

Russell J. Cox

Chief Executive Officer, Epirium Bio

Russell Cox is president, chief executive officer and a member of the board of directors of Epirium Bio. Russell also serves on the board of directors of Gossamer Bio. Previously, he served as chief executive officer and a member of the board of directors at Vital Therapies. He also formerly served as executive vice president and chief operating officer of Jazz Pharmaceuticals. As COO he held responsibility for the company’s Commercial, R&D, Manufacturing, International, and Global Molecule Leadership teams. He worked in a variety of escalating senior management roles from 2010 to 2018, including executive vice president and chief commercial officer from March 2012 to May 2014. From January 2009 to January 2010, he was senior vice president and chief commercial officer of Ipsen Group, and from 2007 until December 2008 he was vice president of marketing at Tercica, Inc., a biotechnology company acquired by Ipsen Group. From 2003 to 2007, he was with Scios, Inc. (acquired by Johnson & Johnson in 2003), where he served as vice president of marketing. Prior to 2003, Russell was with Genentech, Inc. for 12 years, where he was a product team leader responsible for the company’s growth hormone franchise and led numerous product launches as a group product manager. Russell received a B.S. in biomedical science from Texas A&M University.
Bio

V. Bryan Lawlis, Ph.D.

Independent Director

Dr. Bryan Lawlis has nearly 40 years of experience in the biotechnology industry, including extensive experience as a director and officer. He served as CEO of Itero BioPharmaceuticals, LLC from 2011 to 2017 and from 2007 to 2011 was co-founder and CEO of Itero BioPharmaceuticals, Inc. He was president and CEO of Aradigm Corporation from 2001 to 2006. From 1996 to 2001, Bryan co-founded Covance Biotechnology Services and held the positions of president, CEO and executive chairman. He worked at Genentech from 1981 to 1996 and rose to the position of vice president of process science. Bryan’s current board appointments include independent directorships at BioMarin Pharmaceutical, Geron Corporation, and Coherus Biosciences. He holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in biochemistry from Washington State University.
Bio

Alison Lawton

Former President and CEO of Kaleido Biosciences

Alison Lawton is an executive leader with more than 30 years of experience in biopharma and most recently served as president and CEO of Kaleido Biosciences. Prior to Kaleido Biosciences, she served as chief operating officer of Aura Biosciences and OvaScience and worked at various positions of increasing responsibility at Genzyme, and subsequently at Sanofi-Aventis, including as head of Genzyme Biosurgery and prior senior vice president of Global Market Access. Alison currently serves as independent director for X4 Pharmaceuticals and ProQR Therapeutics and has served on the boards of directors of Verastem, CoLucid until its acquisition by Eli Lilly, and Cubist Pharmaceuticals until its acquisition by Merck & Co. She is past president and chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for Cell and Gene Therapy Committee. She earned her BSc in Pharmacology, with honors, from King’s College London.
Bio

Ivana Magovčević-Liebisch, Ph.D., J.D.

President & Chief Executive Officer, Vigil Neuroscience

Dr. Ivana Magovčević-Liebisch has 20 years of senior management experience in biopharma with expertise in corporate development, M&A, IP and legal strategy, and pipeline and product portfolio development. She is currently the president and chief executive officer of Vigil Neuroscience. Prior to Vigil Neuroscience, she was executive vice president, chief business officer of Ipsen, a biopharmaceutical group focused on innovation and specialty care with medicines in oncology, neuroscience and rare diseases. Ivana previously served as the executive vice president, chief strategy and corporate development officer of Axcella Health Inc. From 2013 to 2017, she was senior vice president and head of global business development at Teva Pharmaceutical Industries, where she spearheaded multiple transactions ranging from licensing to acquisitions for the specialty drug business. From 2001 to 2013, she worked for Dyax Corp, rising to the positions of executive vice president and chief operating officer. During that time, she established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor®, for treatment of hereditary angioedema attacks. From 1998 to 2001, she was patent counsel and director of intellectual property at Transkaryotic Therapies. Ivana has a B.A. in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University Medical School and a J.D. in High Technology law from Suffolk University Law School.
Bio

Sandy Mahatme

President, Chief Operations Officer and Chief Financial Officer, RESILIENCE

Sandy Mahatme currently serves as president, chief operations officer and chief financial officer of RESILIENCE. From November 2012 to July 2020, he served as chief financial officer and chief business officer of Sarepta Therapeutics where he led Sarepta’s finance, business development, technical operations, facilities, IT and investor and public relations functions. From January 2006 to November 2012, he worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including senior vice president of corporate development, senior vice president of finance, corporate treasurer, and head of tax. While at Celgene, Sandy built the treasury and tax functions before establishing the corporate development department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing, and global manufacturing expansion. Prior to working at Celgene, Sandy worked for Pfizer Inc. for eight and a half years in senior roles in business development and corporate tax. He started his career at Ernst & Young LLP, where he advised multinational corporations on a broad range of transactions. Sandy holds Master of Laws (LL.M.) degrees from Cornell Law School and New York University School of Law and is a member of the New York State Bar Association. In addition to Aeglea, Sandy is also a board member of Flexion Therapeutics, Inc. and Idorsia Pharmaceuticals, Ltd.
Bio

Anthony Quinn, M.B Ch.B, Ph.D.

President & Chief Executive Officer

Dr. Anthony Quinn most recently served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma until the company’s acquisition by Alexion Pharmaceuticals in 2015. During his tenure at Synageva, he played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency and in building the company’s research and development organization and rare disease drug pipeline. Prior to his role at Synageva, Anthony served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. Previously, he was a professor of dermatology at Barts and The London School of Medicine. He received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and a Ph.D. from the University of Newcastle upon Tyne. He completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London. Anthony currently serves as a member of the board of directors for Kaleido Biosciences, Inc. and Generation Bio.
Bio

Armen Shanafelt, Ph.D.

General Partner, Lily Ventures

Dr. Armen Shanafelt is a general partner at Lilly Ventures. Prior to joining Lilly Ventures in 2009, he had over 24 years of experience in the pharmaceutical, biotechnology, and diagnostic industries. In addition to Aeglea, Armen serves as a director on the boards of Aileron Therapeutics (ALRN), Protagonist Therapeutics (PTGX), Sutro Biopharma, Surface Oncology and Symic Bio, where he serves as chairman. He is a Kauffman Fellow (class of 2014). Armen received his B.S. in chemistry and physics from Pacific Lutheran University and his Ph.D. in chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute.
Bio

Open to Collaboration